Key Highlights

  • Revenue rose 8% to A$42.7 million in the half to 30 June 2026.
  • DAYBUE Royalty income rose 29% in US dollars to US$23.3 million.
  • Net profit after tax fell 68% to A$4.9 million as Research and Development costs rose by A$12.5 million to A$27.4 million.
  • The company declared its first Interim Dividend in its history, 15 cents per share, fully franked.

What does it mean when a clinical-stage biotech pays its first dividend while profit is falling? On 26 August 2026 Neuren Pharmaceuticals (ASX:NEU) reported half-year results to 30 June 2026 and declared a 15 cent per share, fully franked interim dividend, the first in its history. At the same time, net profit after tax fell by about two-thirds as research spending rose. The combination shows a company that now has a royalty income stream large enough to return cash, while still investing heavily in its next drug.

The first-half numbers

Revenue: A$42.7 million, up 8 per cent from A$39.7 million.

DAYBUE royalty income: US$23.3 million, up 29 per cent in US dollars.

Net profit after tax (NPAT): A$4.9 million, down 68 per cent from A$15.0 million.

Basic earnings per share: 3.83 cents, compared with 11.88 cents.

Research and development costs: A$27.4 million, up A$12.5 million.

Interim dividend: 15 cents per share, fully franked, payable in October 2026, under a new dividend policy.

Share buy-back: A$3.9 million of shares repurchased.

An important observation is that the interim dividend of 15 cents per share is much larger than the 3.83 cents of half-year earnings per share.

The royalty engine: DAYBUE and Acadia

Neuren's income comes mainly from royalties on DAYBUE (trofinetide), a treatment for Rett syndrome that is sold in the United States by Acadia Pharmaceuticals under a licence from Neuren. Royalties are a percentage of Acadia's sales, so Neuren has no Manufacturing or sales cost of its own for the product.

Acadia's 2026 net sales guidance was US$480 million to US$510 million. These are Acadia's figures and guidance, not Neuren's, and they can change.

A positive European Medicines Agency opinion has also been received, with a first commercial launch of DAYBUE in Europe targeted for the fourth quarter of 2026.

The pipeline: NNZ-2591

The reason R&D costs rose is largely Neuren's own pipeline. Its lead follow-on candidate, NNZ-2591, is in a Phase 3 study in Phelan-McDermid syndrome, a rare neurodevelopmental disorder. Enrolment numbers and timelines were not given.

This matters because a single-product royalty stream carries concentration risk. Neuren's strategy is to build a second source of value, but clinical development is uncertain: Phase 3 trials can fail, be delayed or require additional data, and regulators can ask for further work. Because of that, the higher R&D spend in this half is a cost with an uncertain payoff, and a material part of the fall in profit.

Competitive and sector context

Rare neurodevelopmental conditions have limited treatment options, and DAYBUE was the first approved therapy for Rett syndrome in the United States.

Key risks

Single-product dependence: Most income comes from royalties on one drug sold by one partner.

Clinical risk: NNZ-2591 may not succeed in Phase 3 or may be delayed.

Rising costs: R&D spend rose by A$12.5 million in the half and could remain elevated.

Capital management risk: A dividend larger than half-year earnings may not be sustainable if royalties or cash fall short of expectations.

Currency: Royalty income is earned in US dollars, while results are reported in Australian dollars, so exchange rates affect reported figures.

European launch uncertainty: Timing, pricing and uptake are not assured.

What to watch next

Several items are worth watching: Acadia's reported DAYBUE sales each quarter, evidence of the European launch in the fourth quarter of 2026, progress and any FDA feedback on the NNZ-2591 Phase 3 program, the October 2026 dividend payment, and further buy-back activity.

Bottom line

Neuren's interim result shows a small biotech whose DAYBUE royalties have grown enough to support a dividend, even as heavy R&D spending depresses profit. The Investment case therefore rests on two things: continued DAYBUE growth through Acadia and the clinical success of NNZ-2591. Both carry uncertainty, and neither outcome can be assumed from the half-year figures alone.